Carbylan Therapeutics, which is developing a novel, injectable treatment for osteoarthritis pain, filed on Monday with the SEC to raise up to $86 million in an initial public offering. The Palo Alto, CA-based company, which was founded in 2004, plans to list on the NASDAQ under the symbol CBYL. Carbylan Therapeutics initially filed confidentially on September 19, 2014. Leerink Partners is the sole bookrunner on the deal. No pricing terms were disclosed.
